Immunitybio Historical Balance Sheet

IBRX Stock

USD 2.71 0.04 1.45%

Trend analysis of Immunitybio balance sheet accounts such as Other Current Liabilities of 26.2 M or Total Current Liabilities of 104.2 M provides information on Immunitybio's total assets, liabilities, and equity, which is the actual value of Immunitybio to its prevalent stockholders. By breaking down trends over time using Immunitybio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Immunitybio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunitybio is a good buy for the upcoming year.

Immunitybio Inventory

13.85 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

About Immunitybio Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Immunitybio at a specified time, usually calculated after every quarter, six months, or one year. Immunitybio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunitybio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunitybio currently owns. An asset can also be divided into two categories, current and non-current.

Immunitybio Balance Sheet Chart

At this time, Immunitybio's Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to about 1.3 M in 2025, whereas Total Assets are likely to drop slightly above 299.1 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Net Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Immunitybio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunitybio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Immunitybio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunitybio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Immunitybio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Immunitybio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunitybio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.At this time, Immunitybio's Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to about 1.3 M in 2025, whereas Total Assets are likely to drop slightly above 299.1 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	723.8M	726.7M	42.3M	40.2M
Total Assets	362.4M	504.5M	382.9M	299.1M

Short Long Term Debt Total Total Assets

Immunitybio balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Common Stock Shares Outstanding
Total Assets		0.65	0.74	0.51	-0.44	0.76	-0.83	0.48	-0.74	0.63	0.84	0.88	0.39	0.91	0.23	0.77	0.66	0.72	0.78	0.74	0.73	0.95	0.42	0.61	0.67	0.54
Short Long Term Debt Total	0.65		0.8	0.79	-0.65	0.74	-0.45	0.96	-0.59	0.83	0.67	0.67	-0.17	0.5	0.02	0.63	0.51	0.7	0.52	0.72	0.62	0.55	0.74	0.45	0.45	0.31
Other Current Liab	0.74	0.8		0.68	-0.67	0.86	-0.73	0.75	-0.79	0.85	0.59	0.8	-0.11	0.53	0.28	0.74	0.65	0.77	0.77	0.79	0.75	0.59	0.57	0.42	0.7	0.54
Total Current Liabilities	0.51	0.79	0.68		-0.51	0.63	-0.41	0.8	-0.5	0.88	0.39	0.58	-0.14	0.34	0.0	0.61	0.27	0.68	0.46	0.58	0.57	0.39	0.98	0.41	0.37	0.19
Total Stockholder Equity	-0.44	-0.65	-0.67	-0.51		-0.77	0.32	-0.56	0.87	-0.63	-0.57	-0.61	0.44	-0.19	0.02	-0.85	-0.88	-0.88	-0.79	-0.92	-0.86	-0.27	-0.41	-0.67	-0.86	-0.76
Property Plant And Equipment Net	0.76	0.74	0.86	0.63	-0.77		-0.77	0.66	-0.89	0.8	0.64	0.94	-0.14	0.46	0.26	0.86	0.76	0.9	0.86	0.87	0.91	0.54	0.53	0.74	0.78	0.75
Current Deferred Revenue	-0.83	-0.45	-0.73	-0.41	0.32	-0.77		-0.34	0.7	-0.59	-0.5	-0.87	-0.26	-0.65	-0.44	-0.66	-0.53	-0.64	-0.77	-0.59	-0.7	-0.69	-0.3	-0.59	-0.62	-0.49
Net Debt	0.48	0.96	0.75	0.8	-0.56	0.66	-0.34		-0.44	0.83	0.45	0.57	-0.23	0.31	0.0	0.47	0.34	0.59	0.36	0.58	0.49	0.35	0.78	0.32	0.29	0.18
Retained Earnings	-0.74	-0.59	-0.79	-0.5	0.87	-0.89	0.7	-0.44		-0.68	-0.68	-0.85	0.1	-0.5	-0.16	-0.97	-0.94	-0.95	-0.99	-0.97	-0.97	-0.57	-0.36	-0.79	-0.98	-0.84
Accounts Payable	0.63	0.83	0.85	0.88	-0.63	0.8	-0.59	0.83	-0.68		0.45	0.78	-0.05	0.38	0.05	0.69	0.48	0.81	0.65	0.72	0.7	0.45	0.81	0.55	0.56	0.38
Cash	0.84	0.67	0.59	0.39	-0.57	0.64	-0.5	0.45	-0.68	0.45		0.66	0.08	0.82	0.05	0.72	0.72	0.66	0.66	0.76	0.66	0.85	0.32	0.57	0.64	0.54
Non Current Assets Total	0.88	0.67	0.8	0.58	-0.61	0.94	-0.87	0.57	-0.85	0.78	0.66		0.19	0.62	0.28	0.83	0.71	0.86	0.86	0.81	0.87	0.68	0.48	0.77	0.75	0.69
Non Currrent Assets Other	0.39	-0.17	-0.11	-0.14	0.44	-0.14	-0.26	-0.23	0.1	-0.05	0.08	0.19		0.52	0.18	-0.07	-0.12	-0.1	0.0	-0.15	-0.12	0.48	-0.13	0.0	-0.09	-0.16
Cash And Short Term Investments	0.91	0.5	0.53	0.34	-0.19	0.46	-0.65	0.31	-0.5	0.38	0.82	0.62	0.52		0.14	0.56	0.48	0.45	0.56	0.53	0.47	1.0	0.28	0.36	0.46	0.29
Net Receivables	0.23	0.02	0.28	0.0	0.02	0.26	-0.44	0.0	-0.16	0.05	0.05	0.28	0.18	0.14		0.11	0.1	0.1	0.2	0.09	0.2	0.16	-0.05	0.01	0.11	0.05
Common Stock Total Equity	0.77	0.63	0.74	0.61	-0.85	0.86	-0.66	0.47	-0.97	0.69	0.72	0.83	-0.07	0.56	0.11		0.89	0.96	0.95	0.97	0.98	0.62	0.5	0.79	0.94	0.78
Non Current Liabilities Total	0.66	0.51	0.65	0.27	-0.88	0.76	-0.53	0.34	-0.94	0.48	0.72	0.71	-0.12	0.48	0.1	0.89		0.85	0.91	0.94	0.9	0.53	0.13	0.73	0.96	0.83
Other Current Assets	0.72	0.7	0.77	0.68	-0.88	0.9	-0.64	0.59	-0.95	0.81	0.66	0.86	-0.1	0.45	0.1	0.96	0.85		0.92	0.96	0.97	0.53	0.57	0.85	0.9	0.74
Other Stockholder Equity	0.78	0.52	0.77	0.46	-0.79	0.86	-0.77	0.36	-0.99	0.65	0.66	0.86	0.0	0.56	0.2	0.95	0.91	0.92		0.93	0.95	0.62	0.31	0.78	0.98	0.81
Total Liab	0.74	0.72	0.79	0.58	-0.92	0.87	-0.59	0.58	-0.97	0.72	0.76	0.81	-0.15	0.53	0.09	0.97	0.94	0.96	0.93		0.96	0.59	0.46	0.76	0.94	0.77
Property Plant And Equipment Gross	0.73	0.62	0.75	0.57	-0.86	0.91	-0.7	0.49	-0.97	0.7	0.66	0.87	-0.12	0.47	0.2	0.98	0.9	0.97	0.95	0.96		0.54	0.45	0.83	0.93	0.78
Total Current Assets	0.95	0.55	0.59	0.39	-0.27	0.54	-0.69	0.35	-0.57	0.45	0.85	0.68	0.48	1.0	0.16	0.62	0.53	0.53	0.62	0.59	0.54		0.32	0.42	0.53	0.36
Short Term Debt	0.42	0.74	0.57	0.98	-0.41	0.53	-0.3	0.78	-0.36	0.81	0.32	0.48	-0.13	0.28	-0.05	0.5	0.13	0.57	0.31	0.46	0.45	0.32		0.33	0.22	0.1
Intangible Assets	0.61	0.45	0.42	0.41	-0.67	0.74	-0.59	0.32	-0.79	0.55	0.57	0.77	0.0	0.36	0.01	0.79	0.73	0.85	0.78	0.76	0.83	0.42	0.33		0.75	0.67
Common Stock	0.67	0.45	0.7	0.37	-0.86	0.78	-0.62	0.29	-0.98	0.56	0.64	0.75	-0.09	0.46	0.11	0.94	0.96	0.9	0.98	0.94	0.93	0.53	0.22	0.75		0.84
Common Stock Shares Outstanding	0.54	0.31	0.54	0.19	-0.76	0.75	-0.49	0.18	-0.84	0.38	0.54	0.69	-0.16	0.29	0.05	0.78	0.83	0.74	0.81	0.77	0.78	0.36	0.1	0.67	0.84

Click cells to compare fundamentals

Immunitybio Account Relationship Matchups

Immunitybio balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	221.4M	468.9M	362.4M	504.5M	382.9M	299.1M
Short Long Term Debt Total	275.5M	645.7M	723.8M	726.7M	42.3M	40.2M
Other Current Liab	51.6M	52.3M	45.3M	43.8M	33.3M	26.2M
Total Current Liabilities	68.1M	369.0M	500.9M	58.3M	54.9M	104.2M
Total Stockholder Equity	(119.8M)	(242.2M)	(447.3M)	(587.0M)	(488.1M)	(463.7M)
Property Plant And Equipment Net	90.7M	119.2M	189.4M	182.7M	170.5M	92.0M
Net Debt	240.6M	464.6M	619.1M	461.3M	(101.1M)	(96.1M)
Retained Earnings	(1.6B)	(2.0B)	(2.4B)	(3.0B)	(3.4B)	(3.2B)
Accounts Payable	11.5M	11.4M	21.0M	9.2M	6.7M	7.2M
Cash	34.9M	181.1M	104.6M	265.5M	143.4M	94.3M
Non Current Assets Total	109.7M	134.6M	221.8M	210.4M	198.3M	124.4M
Non Currrent Assets Other	3.3M	7.2M	6.6M	9.7M	12.0M	15.1M
Cash And Short Term Investments	96.1M	317.1M	107.2M	266.5M	149.8M	159.8M
Net Receivables	2.0M	1.3M	1.9M	3.2M	2.4M	2.7M
Common Stock Total Equity	10K	11K	40K	42K	48.3K	50.7K
Liabilities And Stockholders Equity	221.4M	468.9M	362.4M	504.5M	382.9M	299.1M
Non Current Liabilities Total	271.7M	343.8M	311.3M	1.0B	816.1M	856.9M
Other Current Assets	9.2M	15.9M	31.5M	24.5M	24.1M	25.4M
Other Stockholder Equity	1.5B	1.7B	1.9B	2.4B	2.9B	3.0B
Total Liab	339.9M	712.8M	812.2M	1.1B	871.1M	914.6M
Property Plant And Equipment Gross	67.4M	172.2M	258.7M	267.0M	270.0M	283.5M
Total Current Assets	111.7M	334.3M	140.6M	294.1M	184.6M	174.7M
Accumulated Other Comprehensive Income	122K	4K	183K	10K	1.2M	1.3M
Short Term Debt	5.0M	305.3M	434.6M	5.2M	14.9M	14.2M
Intangible Assets	1.5M	1.4M	20.0M	17.1M	15.9M	16.7M
Common Stock	38K	40K	42K	67K	85K	89.3K
Short Term Investments	61.1M	136.0M	2.5M	1.0M	6.4M	6.1M
Other Assets	1.0	7.6M	6.4M	6.6M	7.6M	4.4M
Capital Surpluse	783.0M	1.5B	1.7B	1.9B	2.2B	1.3B
Property Plant Equipment	27.8M	29.0M	82.9M	143.7M	165.2M	173.5M
Other Liab	8.3M	1.6M	411K	22.0M	25.3M	26.6M
Net Tangible Assets	(118.6M)	(236.5M)	(243.6M)	(467.3M)	(420.6M)	(399.6M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunitybio Historical Balance Sheet

Immunitybio Inventory

13.85 Million

About Immunitybio Balance Sheet Analysis

Immunitybio Balance Sheet Chart

Total Assets

Total Current Liabilities

Net Debt

Immunitybio balance sheet Correlations

Immunitybio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunitybio balance sheet Accounts

Also Currently Popular

Additional Tools for Immunitybio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Debt	+ 0.98	Total Current Liabilities
Property Plant And Equipment Gross	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Other Stockholder Equity
Total Liab	+ 0.97	Common Stock Total Equity
Property Plant And Equipment Gross	+ 0.97	Other Current Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.95	Retained Earnings